Immunotherapy in older patients with melanoma

In this lecture, I will discuss the current evidence for treatment of older adults with advanced/metastasized melanoma with immunotherapy via checkpoint inhibition. We will discuss response rates, treatment toxicity and I will include a section on predictive biomarkers of outcome that are of specific interest for older patients (such as immunosenescence markers).
About me:
I am a registered clinical epidemiologist and working as a fellow in medical oncology in the Netherlands. I have published over 50 manuscripts and have received several research grants. I am particularly interested in research in geriatric oncology and am a an active member of the International Society for Geriatric Oncology.
You can find more information about my work on my linkedin page:
www.linkedin.com/in/nienke-de-glas
And here is my full bibliography:
pubmed.ncbi.nlm.nih.gov/?term...
Disclaimer:
Views and opinions are my own. Examples from clinical research will always include either my own work, or previously published research. I will include references in the description box.

[@colleenfromsydney4194]

Thank you for sharing your knowledge.

[@nicolawilkinson9079]

Thank you for a very informative lecture. My mother is 82 and has been diagnosed with Stage 4 metastatic melanoma and has just started a course of immunotherapy (Nivolumab). This is the first information I have been able to find specifically for older patients. Thanks again.

[@nienkedeglas_mdphd]

thank you for your feedback and I wish you all the best with your mother, I hope she is doing well!